Consensus Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
26.33 ^USD	+3.25%		+0.30%	-21.96%

Mar. 13	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Mar. 13	Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	MT

Evolution of the average Target Price on Pacira BioSciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0f693b3ced52ddac2b732afea8626da._oOltddofyvXzqB_dVG2ci_642ensqm7VXebDEFJv_4.zseXwJoAEFGvtJk-FxbHJnqoixDGwcrDFCjYNCYNzc2stO7QnxosSLH5mA~3b08bc7aabb28727bb992b4c3802b401

Analyst Recommendations on Pacira BioSciences, Inc.

RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating	Mar. 01	MT
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating	Jan. 03	MT
Raymond James Initiates Pacira BioSciences With Outperform Rating, Price Target is $42	Dec. 20	MT
HC Wainwright Adjusts Price Target on Pacira BioSciences to $57 From $63, Maintains Buy Rating	Nov. 06	MT
RBC Cuts Price Target on Pacira BioSciences to $58 From $67, Keeps Outperform Rating	Nov. 03	MT
Barclays Adjusts Pacira BioSciences' Price Target to $57 From $60, Maintains Overweight Rating	23-10-23	MT
Wedbush Lowers Pacira BioSciences' Price Target to $57 From $60, Keeps Outperform Rating	23-08-04	MT
Truist Securities Adjusts Price Target on Pacira BioSciences to $55 From $60, Maintains Buy Rating	23-08-03	MT
TD Cowen Upgrades Pacira BioSciences to Outperform From Market Perform, Price Target is $50	23-08-03	MT
HC Wainwright Adjusts Price Target on Pacira BioSciences to $63 From $68, Maintains Buy Rating	23-08-03	MT
RBC Cuts Price Target on Pacira BioSciences to $68 From $70, Maintains Outperform Rating	23-08-03	MT
Needham Adjusts Price Target on Pacira BioSciences to $52 From $60, Maintains Buy Rating	23-08-03	MT
HC Wainwright Lowers Price Target on Pacira BioSciences to $68 From $71, Maintains Buy Rating	23-07-13	MT
RBC Trims Pacira BioSciences' Price Target to $70 From $72, Keeps Outperform Rating	23-07-07	MT
RBC Cuts Price Target on Pacira BioSciences to $72 From $75, Maintains Outperform Rating	23-05-04	MT
RBC Capital Adjusts Pacira BioSciences Price Target to $75 From $76, Maintains Outperform Rating	23-04-06	MT
RBC Cuts Price Target on Pacira BioSciences to $76 From $80, Maintains Outperform Rating	23-03-01	MT
HC Wainwright Adjusts Price Target on Pacira BioSciences to $71 From $69, Maintains Buy Rating	23-03-01	MT
Wedbush Assumes Pacira BioSciences at Outperform, Cuts Price Target to $60 From $88	23-01-31	MT
Needham Adjusts Price Target on Pacira BioSciences to $63 From $66, Maintains Buy Rating	23-01-06	MT
BMO Capital Adjusts Price Target on Pacira BioSciences to $52 From $60, Maintains Market Perform Rating	23-01-06	MT
BMO Capital Adjusts Price Target on Pacira BioSciences to $60 From $66, Maintains Market Perform Rating	22-11-07	MT
HC Wainwright Adjusts Price Target on Pacira BioSciences to $76 From $83, Maintains Buy Rating	22-11-04	MT
RBC Trims Pacira BioSciences' Price Target to $80 From $82, Keeps Outperform Rating	22-11-04	MT
Wedbush Lowers Pacira BioSciences' Price Target to $88 From $94, Keeps Outperform Rating	22-11-04	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.33 USD

Average target price

45.73 USD

Spread / Average Target

+73.67%

High Price Target

57 USD

Spread / Highest target

+116.48%

Low Price Target

36 USD

Spread / Lowest Target

+36.73%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pacira BioSciences, Inc.

RBC Capital Markets
Raymond James
HC Wainwright
Barclays
Wedbush
Truist Securities
TD Cowen
Needham & Co.
BMO Capital
Jefferies & Co.
Piper Sandler
Northland Securities
JPMorgan Chase
Berenberg Bank
SVB Leerink

Ratings for Pacira BioSciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar